Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab-rzaa which is already approved for intravenous (IV) induction NORTH CHICAGO, Ill., April 27, 2026 /PRNewswire/ -- AbbVie...
Hence then, the article about abbvie submits regulatory application to fda for skyrizi risankizumab rzaa subcutaneous induction for adults with moderately to severely active crohn s disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease )
Also on site :
- Popular Toddler Snacks Sold at Costco, Target and Walmart Recalled Over Potentially Deadly Choking Hazard
- Kraft Mac & Cheese Just Launched 2 Unexpected New Flavors—and One Is Inspired by a Beloved Breakfast Treat
- Grand Circle Cruise Line Black Friday Sale: Save Up to $3,000 on 2027 River Cruises, Plus $1,000 Off for Solo Travelers